相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity
Dianne K. Bryce et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)
Structural analysis of the full-length human LRRK2
Alexander Myasnikov et al.
CELL (2021)
Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?
Ellen Sidransky et al.
MOVEMENT DISORDERS (2020)
Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present)
Xiao Ding et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
Marco A. S. Baptista et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Development of an Aryl Amination Catalyst with Broad Scope Guided by Consideration of Catalyst Stability
Scott D. McCann et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Selective Inhibitors of G2019S-LRRK2 Kinase Activity
Albert W. Garofalo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases
Rachel C. Gomez et al.
JOURNAL OF CELL BIOLOGY (2019)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)
Douglas S. Williamson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Martin Steger et al.
ELIFE (2016)
Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking
Christian A. Lang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity
Soumya Ray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Unique Functional and Structural Properties of the LRRK2 Protein ATP-binding Pocket
Zhiyong Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Type II Kinase Inhibitors Show an Unexpected Inhibition Mode against Parkinson's Disease-Linked LRRK2 Mutant G2019S
Min Liu et al.
BIOCHEMISTRY (2013)
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness et al.
PLOS ONE (2013)
Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
Marco A. S. Baptista et al.
PLOS ONE (2013)
Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011)
Xianming Deng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition
Elizabeth A. Doggett et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway
Youren Tong et al.
MOLECULAR NEURODEGENERATION (2012)
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
Martin C. Herzig et al.
HUMAN MOLECULAR GENETICS (2011)
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
Nicolas Dzamko et al.
BIOCHEMICAL JOURNAL (2010)
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2010)
Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans
Suzanne Lesage et al.
HUMAN MOLECULAR GENETICS (2010)
Cu-Catalyzed Arylation of Phenols: Synthesis of Sterically Hindered and Heteroaryl Diaryl Ethers
Debabrata Maiti et al.
JOURNAL OF ORGANIC CHEMISTRY (2010)
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions
Elisa Greggio et al.
ASN NEURO (2009)
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2009)
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls
Coro Paisan-Ruiz et al.
HUMAN MUTATION (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
A Di Fonzo et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2006)
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease
[Anonymous]
BRAIN (2005)
Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease
L Skipper et al.
HUMAN MOLECULAR GENETICS (2005)
Lrrk2 pathogenic substitutions in Parkinson's disease
IF Mata et al.
NEUROGENETICS (2005)
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
AB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Derivation and validation of toxicophores for mutagenicity prediction
J Kazius et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
C Paisán-Ruíz et al.
NEURON (2004)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
分享论文
